Literature DB >> 10752962

IL-10 and antibodies to TGF-beta2 and PDGF inhibit RPE-mediated retinal contraction.

L Carrington1, D McLeod, M Boulton.   

Abstract

PURPOSE: Retinal pigment epithelial (RPE) cells are believed to play a pivotal role in the formation and contraction of epiretinal membranes in proliferative vitreoretinopathy (PVR). In the present study, an organ culture method was used that mimics the contractile stage of PVR, to investigate the contribution of a variety of growth factors in human RPE cell-mediated contraction of the retina.
METHODS: Cultured human RPE cells were seeded onto bovine retinal explants. After attachment, cultures received one of the following exogenous growth factors: platelet-derived growth factor (PDGF)-AB, PDGF-BB, basic fibroblast growth factor (bFGF), transforming growth factor (TGF)-beta1, TGF-beta2, or interleukin (IL)-10; or a neutralizing antibody to PDGF and/or TGF-beta2. Control explants were either untreated or received a null antibody. Contraction was assessed by image analysis and expressed as percentage reduction in retinal area.
RESULTS: RPE cells produced a more than 50% contraction of the retina after 7 days in untreated samples. PDGF and TGF-beta2 stimulated RPE-mediated contraction by a further 20% at 100 ng/ml. IL-10 decreased contraction by 63%, whereas the other growth factors gave rise to similar contraction to untreated controls. Neutralizing antibodies against PDGF and TGF-beta2 reduced RPE-mediated contraction by up to 70% in comparison with untreated controls. The neutralizing antibodies also inhibited the effects of exogenous PDGF and TGF-beta2 on RPE-mediated contraction of the retina (P < 0.01).
CONCLUSIONS: These findings confirm a role for both PDGF and TGF-beta2 in RPE cell-mediated contraction of the retina. Such contraction can be inhibited by neutralizing antibodies against PDGF and TGF-beta2, which, together with IL-10, are putative candidates for therapeutic intervention in PVR.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10752962

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  15 in total

1.  Smad3 regulates Rho signaling via NET1 in the transforming growth factor-beta-induced epithelial-mesenchymal transition of human retinal pigment epithelial cells.

Authors:  Jungeun Lee; Hyun-Jeong Moon; Jong-Min Lee; Choun-Ki Joo
Journal:  J Biol Chem       Date:  2010-06-11       Impact factor: 5.157

Review 2.  Biomarkers of Diabetic Retinopathy.

Authors:  Daniel Shu Wei Ting; Kara-Anne Tan; Val Phua; Gavin Siew Wei Tan; Chee Wai Wong; Tien Yin Wong
Journal:  Curr Diab Rep       Date:  2016-12       Impact factor: 4.810

3.  TGF-β2 secretion from RPE decreases with polarization and becomes apically oriented.

Authors:  Louis Hirsch; Hossein Nazari; Parameswaran G Sreekumar; Ram Kannan; Laurie Dustin; Danhong Zhu; Ernesto Barron; David R Hinton
Journal:  Cytokine       Date:  2014-12-10       Impact factor: 3.861

4.  Effects of (-)-epigallocatechin gallate on RPE cell migration and adhesion.

Authors:  Chi-Ming Chan; Jheng-Hua Huang; Han-Sun Chiang; Wen-Bin Wu; Hsin-Huang Lin; Jing-Yin Hong; Chi-Feng Hung
Journal:  Mol Vis       Date:  2010-04-03       Impact factor: 2.367

5.  PDGF receptors are activated in human epiretinal membranes.

Authors:  Jing Cui; Hetian Lei; Arif Samad; Sreenivasa Basavanthappa; David Maberley; Joanne Matsubara; Andrius Kazlauskas
Journal:  Exp Eye Res       Date:  2008-11-08       Impact factor: 3.467

6.  Quantitative proteomics analysis of human vitreous in rhegmatogenous retinal detachment associated with choroidal detachment by data-independent acquisition mass spectrometry.

Authors:  Shasha Luo; Huiyan Xu; Lufei Yang; Xuechun Gong; Jinyan Shen; Xuan Chen; Zhifeng Wu
Journal:  Mol Cell Biochem       Date:  2022-03-25       Impact factor: 3.396

7.  Pirfenidone inhibits transforming growth factor-β1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19.

Authors:  Kyungsun Choi; Kihwang Lee; Seung-Wook Ryu; Minju Im; Koung Hoon Kook; Chulhee Choi
Journal:  Mol Vis       Date:  2012-04-21       Impact factor: 2.367

8.  Proliferative vitreoretinopathy: current and emerging treatments.

Authors:  Ama Sadaka; Gian Paolo Giuliari
Journal:  Clin Ophthalmol       Date:  2012-08-14

9.  Troglitazone suppresses transforming growth factor beta-mediated fibrogenesis in retinal pigment epithelial cells.

Authors:  Huey-Chuan Cheng; Tsung-Chuan Ho; Show-Li Chen; Huei-Yi Lai; Kuo-Fu Hong; Yeou-Ping Tsao
Journal:  Mol Vis       Date:  2008-01-18       Impact factor: 2.367

Review 10.  Proliferative vitreoretinopathy after eye injuries: an overexpression of growth factors and cytokines leading to a retinal keloid.

Authors:  Francesco Morescalchi; Sarah Duse; Elena Gambicorti; Mario R Romano; Ciro Costagliola; Francesco Semeraro
Journal:  Mediators Inflamm       Date:  2013-09-30       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.